{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:54:37Z","timestamp":1793994877838,"version":"4.8.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Anaplastic Thyroid Carcinoma (ATC) represents one of the most aggressive and lethal human malignancies, characterized by rapid progression, profound therapy resistance, and a dismal prognosis. Recent advances have underscored metabolic reprogramming as a cornerstone of ATC pathogenesis, enabling tumor cells to adapt to a hostile microenvironment, sustain proliferation, and evade immune destruction. This review systematically delineates how metabolic alterations in ATC\u2014spanning enhanced glycolysis, deregulated lipid metabolism, and aberrant amino acid utilization\u2014orchestrate a profoundly immunosuppressive tumor immune microenvironment (TIME). We explore the mechanistic links between tumor metabolism and immune dysfunction, including nutrient competition-induced energy deficits in effector immune cells, accumulation of immunosuppressive metabolites, and metabolic regulation of immune checkpoint expression. Furthermore, we discuss the impact of metabolic crosstalk on immune cell phenotypes, fostering the recruitment and polarization of pro-tumorigenic immune populations such as M2 macrophages, regulatory T cells, and myeloid-derived suppressor cells. Clinically, we highlight the therapeutic promise of targeting key metabolic nodes and review emerging combination strategies that integrate metabolic inhibitors with immune checkpoint blockade to overcome resistance and enhance antitumor immunity. By synthesizing foundational insights with cutting-edge preclinical and clinical evidence, this review aims to provide a cohesive mechanistic framework and identify novel, metabolism-based therapeutic vulnerabilities for precision immunotherapy in ATC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1699202","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:47:20Z","timestamp":1770187640000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic reprogramming orchestrates an immunosuppressive microenvironment in anaplastic thyroid cancer: mechanisms and clinical perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Jinkun","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baowei","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2023.108174","article-title":"Coexistence of Oncocytic (Hurthle cell) carcinoma with foci of anaplastic carcinoma and a metastasizing papillary carcinoma in one thyroid gland: Rare case report","volume":"106","author":"Assiri","year":"2023","journal-title":"Int J Surg Case Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.08.009","article-title":"Anaplastic thyroid carcinoma: A contemporary review of challenges and advances","author":"Silver Karcioglu","year":"2025","journal-title":"Endocr Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2025.03.009","article-title":"Advances in anaplastic thyroid cancer treatment","volume":"54","author":"Hamidi","year":"2025","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173712","article-title":"A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer","volume":"9","author":"Han","year":"2024","journal-title":"JCI Insight"},{"key":"B5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"168:107513","DOI":"10.1016\/j.oraloncology.2025.107513","article-title":"Turning tumor microenvironmental foes to friends: A new opportunity for thyroid cancer therapy and redifferentiation","author":"Zhu","year":"2025","journal-title":"Oral Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-024-09832-1","article-title":"Unravelling the reasons behind limited response to anti-PD therapy in ATC: A comprehensive evaluation of tumor-infiltrating immune cells and checkpoints","volume":"35","author":"Boruah","year":"2024","journal-title":"Endocr Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1451650","article-title":"Hepatocellular carcinoma cells induce gammadelta T cells through metabolic reprogramming into tumor-progressive subpopulation","volume":"14","author":"Xia","year":"2024","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188928","article-title":"Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities","volume":"1878","author":"Zhang","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12943-024-02165-x","article-title":"Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/imm.70045","article-title":"Molecular mediators of metabolic reprogramming in cancer: mechanisms, regulatory networks, and therapeutic strategies","author":"Ahuja","year":"2025","journal-title":"Immunology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: a cancer hallmark even warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/XCS.0000000000000226","article-title":"Effect of lactate export inhibition on anaplastic thyroid cancer growth and metabolism","volume":"234","author":"Zhao","year":"2022","journal-title":"J Am Coll Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34291","article-title":"Shikonin inhibits the growth of anaplastic thyroid carcinoma cells by promoting ferroptosis and inhibiting glycolysis","volume":"10","author":"Yang","year":"2024","journal-title":"Heliyon"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0344","article-title":"BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation","volume":"30","author":"Wang","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.773028","article-title":"Metabolic reprogramming of thyroid cancer cells and crosstalk in their microenvironment","volume":"11","author":"Bao","year":"2021","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","article-title":"Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics","volume":"16","author":"Jin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2024.2312790","article-title":"Autophagy sustains mitochondrial respiration and determines resistance to BRAF(V600E) inhibition in thyroid carcinoma cells","volume":"20","author":"Diaz-Gago","year":"2024","journal-title":"Autophagy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01223-1","article-title":"Fatty acid metabolism and cancer immunotherapy","volume":"24","author":"Luo","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2016.1086341","article-title":"Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma","volume":"20","author":"von Roemeling","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2764","article-title":"Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target","volume":"100","author":"von Roemeling","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2010.877","article-title":"Thiazolidinediones\/PPARgamma agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer","volume":"38","author":"Mansour","year":"2011","journal-title":"Int J Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.1978","article-title":"Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells","volume":"43","author":"Shiragami","year":"2013","journal-title":"Int J Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2025.110352","article-title":"Isoliquiritigenin suppresses fatty acid synthesis and cancer cell migration in anaplastic thyroid carcinoma through AMPK\/SREBF1 pathway","volume":"766","author":"Chen","year":"2025","journal-title":"Arch Biochem Biophys"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19071834","article-title":"A synergistic anti-cancer effect of troglitazone and lovastatin in a human anaplastic thyroid cancer cell line and in a mouse xenograft model","volume":"19","author":"Zhong","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10682","article-title":"Expression of glutamine metabolism-related proteins in thyroid cancer","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"B29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41419-023-06041-2","article-title":"Co-inhibition of glutaminolysis and one-carbon metabolism promotes ROS accumulation leading to enhancement of chemotherapeutic efficacy in anaplastic thyroid cancer","volume":"14","author":"Hwang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e70413","DOI":"10.1002\/mco2.70413","article-title":"Metabolite to modifier: lactate and lactylation in the evolution of tumors","volume":"6","author":"Zhao","year":"2025","journal-title":"MedComm (2020)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02082-x","article-title":"Lactate and lactylation in cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-022-01017-3","article-title":"Lipid metabolism in T cell signaling and function","volume":"18","author":"Lim","year":"2022","journal-title":"Nat Chem Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jnutbio.2015.11.002","article-title":"Role of lipids in the metabolism and activation of immune cells","volume":"34","author":"Hubler","year":"2016","journal-title":"J Nutr Biochem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.8537","article-title":"Indoleamine 2, 3-dioxygenase regulation of immune response (Review)","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Med Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113062","article-title":"Indoleamine 2,3-dioxygenase-1 involves in CD8(+)T cell exhaustion in glioblastoma via regulating tryptophan levels","volume":"142","author":"Zhou","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01462","article-title":"The metabolic signature of macrophage responses","volume":"10","author":"Viola","year":"2019","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8(+) T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101400","article-title":"Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism","volume":"5","author":"Huang","year":"2024","journal-title":"Cell Rep Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-022-01002-x","article-title":"Metabolic communication in the tumour-immune microenvironment","volume":"24","author":"Kao","year":"2022","journal-title":"Nat Cell Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159473","article-title":"Cross-talk between HIF and PD-1\/PD-L1 pathways in carcinogenesis and therapy","volume":"132","author":"Shurin","year":"2022","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-00280-9","article-title":"Metabolic and epigenetic regulation of T-cell exhaustion","volume":"2","author":"Franco","year":"2020","journal-title":"Nat Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002989","article-title":"Metabolic plasticity of T cell fate decision","volume":"137","author":"Pan","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10238-025-01807-8","article-title":"Metabolic reprogramming of arachidonic acid in clear cell renal carcinoma promotes an immunosuppressive microenvironment by activating MDK signaling pathway","volume":"25","author":"Yao","year":"2025","journal-title":"Clin Exp Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-024-06895-0","article-title":"Elucidating the role of S100A10 in CD8(+) T cell exhaustion and HCC immune escape via the cPLA2 and 5-LOX axis","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0628","article-title":"The mechanisms and clinical significance of CD8(+) T cell exhaustion in anti-tumor immunity","volume":"22","author":"Zhong","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051011","article-title":"Effects of the novel PFKFB3 inhibitor KAN0438757 on colorectal cancer cells and its systemic toxicity evaluation in vivo","volume":"13","author":"De Oliveira","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03725-3","article-title":"PFKFB3 facilitates cell proliferation and migration in anaplastic thyroid carcinoma via the WNT\/beta-catenin signaling pathway","volume":"85","author":"Deng","year":"2024","journal-title":"Endocrine"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8368","article-title":"Anticancer effects of natural phytochemicals in anaplastic thyroid cancer (Review)","volume":"48","author":"Li","year":"2022","journal-title":"Oncol Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5526581","article-title":"Study on the antitumor effect and glycolysis of andrographolide in anaplastic thyroid carcinoma","volume":"2021","author":"Yang","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.03.079","article-title":"Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming","volume":"498","author":"Ma","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0966","article-title":"FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma","volume":"84","author":"Huang","year":"2024","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104910","article-title":"Targeting cancer metabolism: Therapeutic potential of the fatty acid synthase (FASN) inhibitors","volume":"214","author":"Nuzzo","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1555287","article-title":"Metabolic reprogramming shapes the immune microenvironment in pancreatic adenocarcinoma: prognostic implications and therapeutic targets","volume":"16","author":"Song","year":"2025","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-023-1025-7","article-title":"Metabolic interventions combined with CTLA-4 and PD-1\/PD-L1 blockade for the treatment of tumors: mechanisms and strategies","volume":"17","author":"Liao","year":"2023","journal-title":"Front Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010179","article-title":"Metabolic implications of immune checkpoint proteins in cancer","volume":"11","author":"Stirling","year":"2022","journal-title":"Cells"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70110","article-title":"Role of monocarboxylate transporters in cancer immunology and their therapeutic potential","volume":"182","author":"Faghihkhorasani","year":"2025","journal-title":"Br J Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.87292","article-title":"DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation","volume":"12","author":"Mullen","year":"2024","journal-title":"Elife"},{"key":"B60","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","article-title":"Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-024-02205-6","article-title":"Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy","volume":"24","author":"Huang","year":"2025","journal-title":"Mol Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115574","article-title":"Reprogramming the lipid metabolism of dendritic cells in tumor immunomodulation and immunotherapy","volume":"167","author":"Sun","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B63","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-024-01954-6","article-title":"Metabolic regulation of the immune system in health and diseases: mechanisms and interventions","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jare.2022.05.012","article-title":"Immunomodulatory properties of mesenchymal stromal\/stem cells: The link with metabolism","volume":"45","author":"Li","year":"2023","journal-title":"J Adv Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e3934","DOI":"10.1002\/cbf.3934","article-title":"Discovering the strength of immunometabolism in cancer therapy: Employing metabolic pathways to enhance immune responses","volume":"42","author":"Huldani","year":"2024","journal-title":"Cell Biochem Funct"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c11260","article-title":"Nanotechnology reprogramming metabolism for enhanced tumor immunotherapy","volume":"18","author":"Zhou","year":"2024","journal-title":"ACS Nano"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03540-1","article-title":"Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02559-6","article-title":"Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer","volume":"130","author":"Wang","year":"2024","journal-title":"Br J Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41368-024-00310-2","article-title":"Integrative single-cell and bulk transcriptomes analyses reveals heterogeneity of serine-glycine-one-carbon metabolism with distinct prognoses and therapeutic vulnerabilities in HNSCC","volume":"16","author":"Wang","year":"2024","journal-title":"Int J Oral Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.21037\/qims-24-1687","article-title":"Utilizing temporal information to assess metabolic heterogeneity: a study of (18)F-FDG dynamic positron emission tomography as a treatment response biomarker in small cell lung cancer","volume":"15","author":"Wang","year":"2025","journal-title":"Quant Imaging Med Surg"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e5095","DOI":"10.1002\/nbm.5095","article-title":"Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous","volume":"37","author":"Ungan","year":"2024","journal-title":"NMR Biomed"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf253","article-title":"Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumor features and responses to treatment by DHODH inhibitors","author":"Dousset","year":"2025","journal-title":"Br J Dermatol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bioactmat.2025.02.030","article-title":"A micro-metabolic rewiring assay for assessing hypoxia-associated cancer metabolic heterogeneity","volume":"48","author":"Oh","year":"2025","journal-title":"Bioact Mater"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116498","article-title":"Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential","volume":"229","author":"Garg","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12943-021-01486-5","article-title":"Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy","volume":"21","author":"Lian","year":"2022","journal-title":"Mol Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2019.12.008","article-title":"Metabolic regulation of epigenetic remodeling in immune cells","volume":"63","author":"Britt","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1177\/10732748251316604","article-title":"Macrophage polarisation in the tumour microenvironment: recent research advances and therapeutic potential of different macrophage reprogramming","volume":"32","author":"Guo","year":"2025","journal-title":"Cancer Control"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1699202\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:47:21Z","timestamp":1770187641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1699202\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2026.1699202"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1699202","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"article-number":"1699202"}}